Heart Failure NYHA Class II Clinical Trial
Official title:
Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients
The two primary goals of it's management are preventing further disease progression(mortality,hospitalizations and deterioration of left ventricular function)and alleviating patient suffering
Heart failure (HF) is emerging as an epidemic in 3rd world countries. Despite significant therapeutic advances, patients with chronic heart failure remain at high risk for HF progression and death. The two primary goals of its management are preventing further disease progression(mortality, hospitalizations and deterioration of left ventricular function)and alleviating patient suffering.Sacubitril /valsartan (previously known as LCZ696) is a first-in-class medicine that contains a neprilysin (NEP )inhibitor(sacubitril) and an angiotensin II receptor blocker (valsartan). NEP is an endopeptidase that metabolizes different vasoactive peptides including natriuretic peptides, bradykinin and Ang -II. In consequence, its inhibition increases mainly the levels of both natriuretic peptides (promoting diuresis, natriuresis and vasodilation) and Ang- II whose effects are blocked by the angiotensin receptor blocker, valsartan (reducing vasoconstriction and aldosterone release). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04528004 -
Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure
|
Early Phase 1 | |
Not yet recruiting |
NCT01669395 -
Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT05835063 -
A Study to Improve Physician-Youth Communication and Medical Decision Making
|
N/A | |
Completed |
NCT03895073 -
HEart fAiluRe evaluaTion Questionnaire
|
||
Completed |
NCT06233695 -
Gender-based Differences in the Outcome of Treatment With Aldosterone Antagonists in Patients With Heart Failure
|
||
Withdrawn |
NCT03631654 -
Ivabradine in Stage D Heart Failure Patients on Chronic Inotropes
|
Phase 4 | |
Recruiting |
NCT04237701 -
Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System
|
||
Withdrawn |
NCT03947853 -
Clinical Study to Evaluate the Predictive Value of the Heart Failure Questionnaire (HF-Q) for the Occurrence of Μajor Αdverse Cardiovascular Events (MACE) in Patients With Symptomatic Heart Failure
|
||
Recruiting |
NCT05487365 -
Implementation and Cost-evaluation of a Smartphone-based Telemonitoring and Digital Support in Patients With HF
|
N/A | |
Not yet recruiting |
NCT06270875 -
Addressing Pain Through Navigator-Led Palliative Care Optimized for Heart Failure (ADAPT-HF)
|
N/A | |
Completed |
NCT03592836 -
Diuretic Response in Advanced Heart Failure: Bolus Intermittent vs Continuous INfusion
|
Phase 3 | |
Not yet recruiting |
NCT06097481 -
Narrative Intervention for Chronic Illness- Heart Failure Trial (NICI-HF)
|
Phase 1/Phase 2 | |
Completed |
NCT03387813 -
Hemodynamic-GUIDEd Management of Heart Failure
|
N/A | |
Completed |
NCT03580759 -
Exergaming in Advanced HF With Multiple Chronic Conditions Prior to LVAD Implantation or Heart Transplant
|
N/A | |
Completed |
NCT04180696 -
Mid-Q Response Study
|
N/A | |
Recruiting |
NCT01774656 -
Remission From Stage D Heart Failure
|
Phase 4 | |
Active, not recruiting |
NCT02880358 -
Epidemiology and Prognostic of the Acute Heart Failure
|
N/A | |
Completed |
NCT04153890 -
Family Palliative and End-of-Life Care for Advanced Heart Failure
|
N/A | |
Recruiting |
NCT05647213 -
Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease
|
Phase 1 | |
Recruiting |
NCT05575336 -
Assessment of the Effectiveness, Socio-economic Impact and Implementation of a Digital Solution for Severe Patients
|
N/A |